ANDEMBRY is the first and only prophylaxis treatment that inhibits the HAE cascade at the top
Preventing HAE attacks at the first move
Effective from Week 1 and continued protection
through 2 years — and counting.1-3
ONLY ANDEMBRY, a monoclonal antibody, inhibits FXIIa at the top of the HAE pathway
ONLY ANDEMBRY offers once-monthly dosing from the start for all patients with no reports of injection-site pain3*
* In the VANGUARD pivotal phase 3 trial.
References: 1. Staubach P, Tachdjian R, Li HH, et al. Timing of onset of garadacimab for preventing hereditary angioedema attacks. Clin Exp Allergy. 2024;doi:10.1111/cea.14568 2. Magerl M, Reshef A, Farkas H, et al. Long-term efficacy and safety of subcutaneous garadacimab for prophylaxis of HAE attacks: results from a multicenter phase 3 study (VANGUARD) and open-label extension. Poster presented at: the European Academy of Allergy and Clinical Immunology Annual Congress; June 9-11, 2023: Hamburg, Germany. 3. Craig TJ, Reshef A, Li HH, et al. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet. 2023 Apr 15;401(10384):1266]. Lancet. 2023;401(10382): 1079-1090. doi:10.1016/S0140-6736(23)00350-1.